Skip to main content
Trever Bivona, MD, Oncology, San Francisco, CA, UCSF Medical Center

TreverGBivonaMD

Oncology San Francisco, CA

Assistant Professor, Medicine, University of California, San Francisco, School of Medicine

Dr. Bivona is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bivona's full profile

Already have an account?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2011
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2005 - 2007
  • New York University School of Medicine
    New York University School of MedicineClass of 2005

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - 2025
  • NY State Medical License
    NY State Medical License 2007 - 2012

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Publications & Presentations

PubMed

Journal Articles

  • Aurora Kinase A Drives the Evolution of Resistance to Third-Generation EGFR Inhibitors in Lung Cancer  
    Victoria E Wang, Collin M Blakely, Trever G Bivona, Andrei Goga, Nature
  • Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping Mutation  
    Julia K Rotow, Trever G Bivona, Collin M Blakely, Clinical Lung Cancer
  • RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven Cancers  
    Trever Bivona, MD, Nature

Authored Content

  • Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationNovember 2018

Press Mentions

  • Damon Runyon Cancer Research Foundation Awards over $4.1 Million to Exceptional Early-Career Scientists
    Damon Runyon Cancer Research Foundation Awards over $4.1 Million to Exceptional Early-Career ScientistsJuly 28th, 2022
  • Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising Investigators
    Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
  • Novel Structure Found in Tumor Cells May Open Door to New Kinds of Cancer Therapies
    Novel Structure Found in Tumor Cells May Open Door to New Kinds of Cancer TherapiesMay 11th, 2021
  • Join now to see all

Hospital Affiliations